Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H21NO2.ClH |
Molecular Weight | 343.847 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1=NC(CC2=CC=CC=C2)=C3C=C(OC)C(OC)=CC3=C1
InChI
InChIKey=DULZSDGCXSLVAQ-UHFFFAOYSA-N
InChI=1S/C20H21NO2.ClH/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14;/h5-9,11-13H,4,10H2,1-3H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C20H21NO2 |
Molecular Weight | 307.3862 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Moxaverine, a derivative of papaverine, is a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related macular degeneration and primary open angle glaucoma. In addition, it has been studied in phase II of the clinical trial for the treatment of ischemia. This compound is prohibited by FEI (International Federation of equine).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2854468 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Construction and validation of a microprocessor controlled extracorporal circuit in rats for the optimization of isolated limb perfusion. | 2004 Dec |
|
Tissue distribution of moxaverine-hydrochloride in the rabbit eye and plasma. | 2005 Jun |
|
Effect of systemic moxaverine on ocular blood flow in humans. | 2009 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00709449
intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3415714
Using a combination of techniques to assess quantitatively the shape and the filterability of red blood cells (RBC) after exposure to stress conditions (400 mosmol/l, lactacidosis, pH 6.8), the effects of 1-benzyl-3-ethyl-6,7-dimethoxy-isoquinoline hydrochloride (moxaverine-HCl, Kollateral) were tested. The shape of freely suspended RBC was quantified using the tangent count procedure. Moxaverine, when present in doses between 10(-5) und 10(-2) mol/l while the RBC are stressed, restored both the normal discoid red cell configuration and the microrheological performance when tested under low shear stresses. The data showed that moxaverine exerted protective effects on RBC membrane curvature and whole cell microrheological behavior (performance).
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 01:49:52 UTC 2023
by
admin
on
Thu Jul 06 01:49:52 UTC 2023
|
Record UNII |
6R0I0E99CN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
214-607-5
Created by
admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
|
PRIMARY | |||
|
DBSALT002165
Created by
admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
|
PRIMARY | |||
|
236673
Created by
admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
|
PRIMARY | RxNorm | ||
|
DTXSID80151342
Created by
admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
|
PRIMARY | |||
|
1163-37-7
Created by
admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
|
PRIMARY | |||
|
6R0I0E99CN
Created by
admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
|
PRIMARY | |||
|
M7644
Created by
admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000085685
Created by
admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
|
PRIMARY | |||
|
70881
Created by
admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
|
PRIMARY | |||
|
SUB03341MIG
Created by
admin on Thu Jul 06 01:49:52 UTC 2023 , Edited by admin on Thu Jul 06 01:49:52 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |